Good morning, and welcome to the Jefferies Global Healthcare Conference in London. My name's Mike Sarcone. I'm an analyst on the U.S. Medical Supplies and Devices team at Jefferies, and this is a session for Align Technology. Up on the dais with us, we have Joe Hogan, CEO, and John Morici, CFO. Also joined in the room is Jennifer Davis, incoming CEO, and Shirley Stacy, Head of IR. Thank you very much for joining us today, gentlemen.
Of course.
Thanks, Mike.
I guess just to kick off, Joe, a few weeks ago in conjunction with 3Q results that you reported, you announced your planned succession and retirement. Maybe we were hoping you could comment on the timing and the announcement, and then just give us your thoughts on the positioning of the company as you hand over the reins.
Yeah, sure. I've been with Align for 11 years now. I'm sorry, Align. I left ABB to join Align 11 years ago. 11 years, I think, is long enough. I'm 69 years old. I'm approaching 70 years old in May next year, and I think it was time for me to stand back from the business and also take another look at life. We've had a really good process internally in the sense of looking at candidates over a year and a half period. Jennifer turned out just a terrific candidate for the job, and I couldn't be more excited about turning over the role to Jennifer. She has a terrific background for us from her P&G time together. We've been beginning this transition over the last couple months, and we'll finish it through December.
I feel really good about the status of the business and Jen's ability to take it over.
Okay, great. Well, we wish you the best. It's been great working with you, and we're looking forward to working with Jennifer as well. I guess maybe, shifting gears, touch on the macro a bit. On the 3Q call a few weeks ago, you mentioned or you characterized discretionary dental and ortho demand as challenged. Maybe you can elaborate more on what you're seeing and how it varies across region and channel.
Yeah. I'd say nothing really changed in the third quarter from what we talked about before. Obviously, consumer demand is a big variable in our equation overall, and we know consumers are challenged. Our business is mostly out-of-pocket costs in that sense. But overall, we felt good about our performance in third quarter across the globe in different areas. Obviously, some products that we've announced recently, which are more, I think, viable from a consumer standpoint in lowering prices, like the Zero AA product was a big help. We had a real dichotomy between Invisalign sales, which did fairly well, versus iTero, which obviously year-on-year was down. But we did sell more units from an iTero standpoint, which lays a really good foundation for the business overall for growth in the future, because we know more iTero placements will work.
Overall, no surprises in the third quarter.
Okay.
I thought the team executed well. John, you have anything to add?
No. I mean, it is a similar environment that we have seen for a number of quarters now. As Joe said, we want to do things in a tough environment to help with our doctors, lower some of the upfront costs, and some of our technology and products are able to do that with the Zero AA or even going a ways back, the three and three, which was moving from the comprehensive unlimited to help with lowering the upfront cost, and then also helping with patient financing. Doing a lot of things to try to connect that patient who might be reluctant to go into treatment. If there are things that we can do to get them into treatment with the financing and so on, we think that helps differentiate, and that is something that we have had to do for several quarters, and we are seeing good momentum around those two aspects.
Okay. That makes sense. I guess, we are midway through calendar 4Q. Have you seen relative stability versus what you saw in 3Q, and any changes to note, I guess, as it relates to the macro?
When we made our forecast for 4Q, it was based on we were already through the month of October, so our forecast pretty much reflects what we've seen between the two quarters.
Okay. On the aligner side, you lowered your 2026 sales guide primarily due to the scanner revenues. You just mentioned that. It also included, we can call it a modest moderation in your outlook for aligner growth. I think it implies maybe aligner sales decelerate to about a low single-digit pace in 4Q. I guess, can you just speak to kind of guidance construction and, I guess, what was incorporated in there?
Yeah. As Joe said, we wanted to be able to include what we saw as we went through third quarter, what we saw starting fourth quarter, be prudent about our guidance so that we could reflect what the demand looks like, not just in North America, but across the globe. That was a reflection of that. As you said, the majority of adjustment was really due to iTero. It's just not for a lack of volume. The units have been great.
Install base is up double digits. We really feel good about the placement and what's happening with iTero. It's really around the pricing that we've seen, so some of the discounts that are needed to be able to get those placements. It's also around some of the mix that we have in iTero. That's really the reflection that we've had with our guidance. But the rest of the business, really not a change from what we've seen in the past.
Okay. I mean, could you characterize at least, again, the modest downgrade in the outlook for aligner sales, more prudence and conservatism?
Yeah, I think it is a reflection of what we see.
Okay.
That gets into our guidance based on that prudence.
Okay.
Yeah. It is a challenging economy that we see, and we want to be able to reflect that -
All right.
-i n those markets.
I guess last year, there was kind of a brief blip where we talked about seeing a shift towards brackets and wires, right? Are you seeing anything like that taking place in the market?
No, I wouldn't say there's any continuity-
Okay.
- in that. I mean, you hear that at times and see that at times. Remember, we're roughly 75% adults and 25% teens. In general, the market's completely inverted to that, and mainly wires and brackets. I feel when we look at our phase 1 products, when you look at IPE, Invisalign Palatal Expander, Invisalign First continues to do extremely well too. Obviously, we have some Class 2 devices like mandibular advancement. Really good progress in those areas too. So no, I'm not expecting a wires and brackets comeback. They have obviously a good moat based on the orthodontic professionals that are out there. But I feel really good about the products that we have in that specific segment, both with more mature teen dentition, but also primary dentition.
Some of it's product-related too. So we have the Zero AA type products. That really helps win the gray area between some of those orthodontists on whether they use wires and brackets, or maybe now the upfront cost is lower for them with the Zero AA product. So, you start to see higher utilization. We've seen good doctor growth, where our submitters have been up, and we saw a good quarter of that in the third quarter. We saw North America ortho up as well.
Yeah.
There's going to be puts and takes as you go through. Sometimes there's more volume or not on wires and brackets and so on, but we feel like we're on the right track to make inroads.
Got it. Just as a quick follow-up to the Zero AA, or zero upfront cost, are you seeing that improve your ability to maybe gain back share?
We definitely see it winning the doctors in the gray area. You think about it, if they're going to stay upfront and they're going to have wires and brackets, it might cost $200 or $300. A Zero AA product, depending on their discount, might be $800, $850. Yes, it's still more than wires and brackets, but I think people understand the digital benefits that digital orthodontics, like what we provide, can give. So it helps win those gray areas, and you get more and more doctors to try. When we've seen this pretty much now across the globe, I mean, our Zero AA products are up triple digits on a year-over-year basis. So, it is taking the adoption, and it's not just a mix shift between other products. This is something that is seeing greater utilization, which we're pleased about.
It's also been able to help us maintain our ASPs, because the way we recognize revenue, we don't defer any revenue -
Right.
- because there's no refinements that come later. So, our ASPs on a year-to-date basis through October are about flat year over year. So, it's really doing what we wanted it to do, and it really comes down to being able to have the technology to give to a doctor so that in one go, they can finish treatment.
[inaudible], there's been an evolution here too, where orthos have been using our product for a number of years now, too. They don't need the five AAs or three AAs. They're very confident. They see a case and say, "I can do this in Zero AAs," or whatever. So, it is a natural movement of confidence. You see it less on the GP side, but much more on the ortho side as they assess cases and do it. So, we're excited about it. We think it's a-
Yeah.
-i t's a good play for us.
Got it. I guess a reach question here. As you exit the year, can you give us a rough ballpark of what percentage of your cases are comprised with the Zero AA now?
We haven't given out that percentage. I would say if you went back to history, at the beginning of 2023, when we had the three and three. Remember, we had comprehensive, which back in our, at that time, was 75% of our portfolio. We introduced a three and three, and I want to say in 18 months, it was then our biggest selling product. It is still the three and three, which is the comprehensive with three refinements. I would say the Zero AA product will give a run for its money on that over time.
Okay.
As Joe said, doctors have to have the clinical confidence to be able to treat these cases, be able to finish in maybe no refinements or one refinement. It's just how doctors want to buy. It's like all of us. Sometimes you buy a service plan upfront on a product, and sometimes you don't. These are doctors who want to pay for the service as they need to going forward.
There's a lot of questions on this, Mike, and I think I'll just add one other thing too, that I never liked that when we were at five AAs or whatever, is the economics of the orthodontist at that point in time aren't in line with ours.
There's a perfectionism in this industry. We'll say, "Well, I might try another aligner. Maybe I'll just close that diastema a little bit more." This puts the economics of the doctors in line with our economics too, and I think that's really healthy for both ends of the course.
Sure. Okay. We mentioned the updated guidance implies maybe low single-digit growth for clear aligners. As we look to 2027, is that low single-digit growth a good jumping off point for the year? Or I guess, how do we think about that as we look to next year?
Well, we haven't guided for. Our plan would be as, get through the fourth quarter and give a good update to that. Again, we'll reflect what the market is. There's a reality of that. You'll also see us reflect what we are doing within the market, some of the products that we talked about, some of the financing, other things that we're doing to help grow. I would say this, on iTero, the expectation is some of the changes that we have and some of the pricing and mix that we've seen, that's stabilized. We talked about that -
Right.
- in the third quarter, and that is the expectation that we have such that we can build off of that into next year.
Just on iTero too, obviously, the year has been difficult, but this is the best scanner in the world overall. And it is well-positioned in both restorative and also on the orthodontic side too. It is just, we want to make sure that we, again, create options out there that allow us to penetrate different parts of the marketplace and to continue to open up the marketplace for us too.
Sure. Okay. I have more questions. I want to double-click on iTero, but I did want to ask, we are getting a bunch of questions on China VBP, so I wanted to give you a chance to give your thoughts on how that may impact you guys.
Yeah. When you ask that question, I go back. We have been doing this dance for four years now. The VBP is coming from an orthodontic standpoint, and every year we take it seriously, and we take it seriously this year too. We always start with the 85% of our business in China is private.
That means it's tier one, tier two hospitals also. We're not in many tier three, two, four We have a completely self-contained business in China with manufacturing, with treatment planning, and all those areas. We're treated as a Chinese company in that kind of piece. We feel good about our ability to compete in the VBP environment. We've positioned products properly that you have to do in order to address that. We don't know if it's coming or not. There's no certainty to it. We've watched the implant business very closely and how that it will expand the overall, I think, philosophy of aligners in that country if that goes through. We think we could benefit from that. At the same time, if it doesn't, we feel confident about our position in China too. John, what would you add?
From the overall standpoint, China's less than 10% of our overall revenue.
ASP is much lower than our average, sub $1,000. We've been able to position our portfolio even before VBP. I mean, the market really was dictating lower price, a lot of these, not as many refinements in some cases, moderate cases, maybe some light cases. The market has already kind of pushed, in many cases, that portfolio down from a pricing standpoint that we've experienced over time and being able to operate within that. So, as Joe said, we're in China for China as the costs will change, and we're reflecting that both in the manufacturing side as well as how we would have to go to market to be able to offset that. When we think about our overall framework for 2027, it's in our thoughts as-
Okay.
- how we've thought about this.
Is it fair to assume, given, Joe, you mentioned this would probably grow penetration of aligners in China, there will be some price offsets to that? Is the thought that the volume more than offsets any-
You certainly get the volume benefit. I mean, there is an overall price pressure that we would see in this.
Sure.
We are way under-penetrated in this market. When you think about clear aligners in China, it is less than 10% of the market. So we are coming from a position of, "W e want to get higher penetration. We want people to be able to experience Invisalign within China." So we have got that on the private side. We would love to see this on the public side. We want to participate in this because it gives us the opportunity to grow the business, but you want to be there in the future to be able to help with growing the overall market share within. So it is a positioning that we want to be a part of. It is something that it works well for us there, and our portfolio and the way we are set up from an operating standpoint really sustains that.
Okay, great. My last one on that would just be, when we do get guidance for 2027, you will give us more of the underlying assumptions around volume and price that you are thinking about?
We'll give you more about that, to give the details. We have talked about the 100 basis point improvement for next year, and that includes the overall framework -
Okay.
- that we're talking about when we talk about with China and so on. Because really, as Joe said, you're looking at maybe a second half impact to this. It's a very small part of our business to start. You get some volume benefit and some of the margin is a minimal impact for next year.
Okay. Awesome. Moving to scanners, you've been talking pretty consistently about volumes being very healthy. I guess, can you elaborate on that? What are the drivers of the pretty healthy volume growth that you're seeing? Are there different pockets of demand geographically?
Yeah. I think you break the market up, the restorative and the orthodontic marketplace. We have good, strong penetration with iTero across the orthodontic markets across the world. Now, they do add more scanners per chair, and we work that piece. But overall, our penetration is really strong there. You have seen us move more toward general dentistry from a restorative standpoint, and also labs.
And obviously service those pieces too. Big improvement in the sense of the way you can scan. You can do upper mouth. We have a really wide coverage in that scanner for palates. If you have two or three implants at one time, you can take one scan and do those three implants like no other scanner in the world can. Labs recognize this, and general dentists recognize this too. So we feel good about, we are very under-penetrated in that restorative piece, and iTero has a fit there. At the same time, we will continue to work hard on the orthodontic side. We would love to see a scanner per chair-
Okay.
- obviously, in an orthodontic office. And orthodontists would like to have that too. Our price points are more amenable to that also.
We will continue to focus on all 3 of those areas.
Okay. Talking about double-digit scanner install base growth, how do you think about the sustainability? You talked about being under-penetrated in general and resto, but also the opportunity to get maybe a scanner at each chair on the ortho side. I guess, can you speak to the sustainability of that double-digit install base growth?
Yeah, I think, when we developed the platform for iTero Lumina, it is not a mirror-based system. It is not confocal imaging. Those are the two predominant platforms that are out there. We developed that platform because we could do a lot of iterations from it. So there are ways to take cost out of that platform. There is a way to make it more specific to certain types of restorative and orthodontic procedures.
You will see us work on that. We are not announcing anything today, but that is a platform we will continue to enhance and allow us to be more competitive in the marketplace.
Okay. Great. Talking about pricing appearing to stabilize, you mentioned that for 3Q. It sounds like, per your commentary around 4Q trends when you guided. That is a trajectory that continued into the fourth quarter. Is there any reason why price would not remain stable as we head into 2027, or is that a reasonable assumption?
On a like-for-like, we would expect pricing to be stable. You do get doctors who maybe they don't want a full system, they want to have the laptop version, and that's just a lower ASP product.
That's okay. Where you also do see some, really coming down to the economics, some doctors, they might have bought in the past, and now they want to lease or they want to rent.
Okay.
That's what we see in a lot of markets, like a China, like a Brazil already. That's gone to that already. In the Western world, you're just seeing that play out. U.S., it's become more, and you're seeing that in parts of Europe as well. They want to use the scanner. We want to see that come. That is going to be lease revenue that you're going to get in the future.
Sure.
Maybe it displaces it in that current period, but you get the benefit later. On a like-for-like, we don't expect to see too much of a change there. It's just a matter of the mix shift that they might want to have.
Do you think this business can return to growth on a sales basis in 2027?
iTero? The expectation is that it does. It might not grow as fast as Invisalign. We usually say that they go about equal.
We will see how that plays out. It really comes down to the capital equipment market and what doctors are feeling like in their practices and so on. But we are properly positioned there, as Joe said, with the type of scanner that we need. There will be iterations to the scanner to get upgrades and others that those doctors might want. We want to find different ways for those doctors to use our equipment, and iTero is a great platform for that, whether it is the product configuration or leasing and rental options that they might have.
Okay, great. I did want to shift gears again. You mentioned 100 basis points of adjusted operating margin expansion in 2027, which is a great target. Can you talk about the key drivers there and maybe how that breaks up between gross margin and operating?
The expectation is that it will be a little bit more balanced between gross margin and OpEx margin. This year, it has been mostly on the gross margin. It starts with some of the product configuration that we are talking about. When we do not have refinements, the gross margin on a product like that, much higher than if you have to do a lot of refinements and fulfilling this later. Product configuration is helping, lower refinements, better gross margin. You see that in a large part of our portfolio. You see also, too, some of the restructuring that we have talked about over the last couple years are really starting to play off. What you have is, where we had a lot of manufacturing in places like Mexico, some of that manufacturing has now moved to China to really help with APAC.
Some of it has gone to Poland to help here in Europe. You see us talking about having expansion in places like India, where right now it is being serviced out of Mexico, and there is a lot of freight, a lot of duties, a lot of extra cost to get there, and it is a very high-growth market for us. Now to be there, it pretty much drives productivity on day one. You get those benefits.
Some of that productivity is just around programs getting closer to our customers, as you know, and that is why we have not had as much of some of the headwinds this year. Even though freight has been more expensive, all companies are seeing higher fuel prices. Fortunately for us, getting closer to our customers, we reduced the amount of air freight, you reduce the amount of trucking costs and so on, and that has really helped us. Some of it is product-related, some of it is just related to the structure that we have from our overall cost savings, and we think that is very durable.
I think as you go into next year, some of the go-to-market activities that we have to really drive productivity, looking at layers, looking at span of control, looking at things to be able to help drive some of that OpEx savings as well, we think that leverage will sustain into next year and feel good about how we are positioned.
Okay. Can you talk about, we have a somewhat challenged consumer that we talked about. Is that the assumption that is baked into that 100 basis points margin expansion?
The assumption is that no change -
Okay.
- really for the consumer.
Yeah, we are not economists.
Yeah.
We're just going to run this thing until it changes.
But it's similar type of consumer, but things that we're doing to be able to help unlock that consumer who's maybe more cautious.
In a scenario where we did see a consumer recovery, presumably that could be some decent upside.
We'd like to see more of those months. You see Michigan Index or other indices that you use, but you want to start seeing more of that trend. But we know that our product, it's somewhat discretionary, maybe not a lot of reimbursement, and if you can get some of those overall consumer to be a little bit more feeling like they want to go into treatment, that's a good thing for us.
Stronger consumer is a good thing for this business.
Okay. You did also mention on the 3Q call the Invisalign Sports Guard. Can you just talk about the revenue opportunity there and the strategic rationale behind it?
Yeah. That's a derivative of our 3D printing technology overall. So what we do is we use the same printing machines out of Austria, Cubicure machines, different viscosity resin. If you look at the sports guard marketplace, it is about $6 billion-$8 billion, depending on how. It goes back to when I played sports, it's still primarily boil-and-bite, right?
They're uncomfortable. People take them out of their mouths. What this allows you to do is to tailor-make a mouth guard for someone much more comfortable than it could be before. The properties are 40% less material needed for the same impact resistance.
We can take a lingual cutout in the back. A person playing sports can actually talk to their teammates, right, and breathe better during that piece. Our channel is really good. Orthodontists love this channel because they can get into the teen segments in their particular zip code, scan those patients for mouth guards, but also use that as an adjacency to be able to move on to tooth treatment overall. It is just a natural brand extension for this business, and it is a natural extension of the technology that we have developed through 3D printing. John, you-
When you think about it is added revenue that we do not have, so that is great. We will start to build on that. We are seeing a lot of demand from doctors who want this as part of their practice, because as Joe said, not only is it added revenue for all of us, but it is a lead generator. Now you can have doctors, ortho or GP, that can scan the kids on a football team or other parts of sports where they can get some access to those potential teens or pre-teens, and being able to then show their parents what their treatment would look like. It is a natural evolution. It is based on our technology that we have, the direct fabrication, and we are really excited about it. We are getting a lot of pull from our doctors to really want this to be part of their portfolio, so we are encouraged by those early results.
You said, "What could it be?" Our retainer business is $500 million , right? When you look at the size of this marketplace, you look at the channels we run it through, there is no reason it cannot be in that kind of a range-
Okay.
- overall, from what we can see.
All right. We only have a little bit of time left, so Joe, I figured maybe we'll give you an opportunity to close out the session with your message to the investment community.
Yeah. Well, overall, as I leave Align, I leave with a lot of confidence in Jen Davis, as I mentioned before. I've been working with Jen now for 40 days or so, and I love the insight, curiosity, and the experience that she has. I think, I grew up in GE, and at GE, you got to see great leaders, right? You saw different businesses at different times. It was just almost like a university to be able to grow up and to really learn business. I see the same thing with Jennifer from her P&G days, the same kind of questions. She's been around great leaders in her life. She's gotten to do that. So, it gives me so much confidence in being able to hand off this business to hand it off to someone with that kind of experience.
At the same time, I could not be more excited about Align. I wish I was 50, okay, and I could stay another 10 years. I really believe in this business. I love this business. The 3D printing piece will revolutionize this industry. You haven't asked a lot of questions about that, but we put a lot of money into this, and it'll change it. Overall, when you can change the geometry of these aligners for different forces at different times, you'll speed and accelerate the timing of these. We're looking at maybe possibly nighttime wear rather than 20-, 18-hour wear that we have today. You can combine so many things that cost us money today when you put on, if you have tabs or you have mandibular advancement and those kind of things, could all be done in one shot at one time.
And then back to iTero, the best scanner in the world, best platform, and we will work that too. I leave here with a lot of confidence in the business and a huge amount of confidence in Jen taking over.
Awesome. We really appreciate your insight and your time. Joe, John, thank you very much for being up here with us.
Thanks.
Okay.